Skip to main content
. 2021 Nov 9;16(11):e0259812. doi: 10.1371/journal.pone.0259812

Fig 1. Features of CRISPR/Cas RNP delivery methods suitable for development of cell-based therapies and those considered ‘research-use only’.

Fig 1